Novo Nordisk A/S vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends

SG&A Expense Trends: Novo Nordisk A/S vs Amphastar Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Novo Nordisk A/S and Amphastar Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Novo Nordisk's SG&A expenses have surged by approximately 130%, reflecting its aggressive market expansion and investment in global operations. In contrast, Amphastar Pharmaceuticals has seen a more modest increase of around 99% in the same period, indicating a steady yet cautious approach to growth.

This divergence highlights the contrasting strategies of these two companies. Novo Nordisk's significant investment in SG&A suggests a focus on scaling and market penetration, while Amphastar's more conservative spending may point to a strategy centered on sustainable growth and cost management. These insights provide a window into the strategic priorities shaping the future of these pharmaceutical giants.